ETFs with GILD as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|8.51%||iShares NASDAQ Biotechnology Index Fund (IBB)||+41.15 (29.59%)|
|5.7%||First Trust Amex Biotechnology Index Fund (FBT)||+12.65 (27.06%)|
|5.43%||PowerShares Dynamic Biotech &Genome (PBE)||+6.20 (26.78%)|
|5.41%||PowerShares Dynamic Pharmaceuticals (PJP)||+7.20 (20.36%)|
|4.16%||Columbia Select Large Cap Growth ETF (RWG)||+7.33 (26.25%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Gilead Sciences, Inc. (Gilead, we or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world. Gilead's primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV), serious cardiovascular and respiratory conditions, and oncology/inflammation. Headquartered in Foster City, California, we have operations in North America, Europe and Asia. We continue to add to our existing portfolio of products through our internal discovery and clinical development programs and through a product acquisition and in-licensing strategy. ... More ...